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Abstract Background: Bacterial 
meningitis in the newborn is glob-
ally renowned for high mortality. 
The associated morbidities also 
include audiologic, motor, visual 
and mental deficits.    
Objective: To highlight the peculi-
arities in the current diagnostic and 
management strategies in newborn 
meningitis. 
Methods: Relevant literature on the 
subject published only in English 
language or translated to English 
language was searched manually 
and electronically. The Medline, 
PUBMED and HINARI were 
searched for the period between 
1966 and 2012. The following key 
words were used during the search: 
newborn/neonatal , bacter ia l /
pyogenic meningitis, central nerv-
ous system infections, antibiotics, 
dexamethasone and fluid  
restriction.  
Results: The pattern of bacterial 
aetiology and mortality differ be-
tween the developed and develop-
ing world. The usefulness of bacte-
riologic culture in the diagnosis of 
meningitis can be improved with 
serologic method like polymerase 
chain reaction. Widespread resis-
tance of pathogens may be threaten-
ing the use of penicillins and gen-
tamicin for empirical treatment of 
newborn meningitis. No sufficient 
evidence presently supports the 
current practices of fluid restriction, 
prolonged duration of antibiotic 
treatment and non-use of adjuvant 
steroid therapies in the newborn.  
Conclusion: Efforts to reduce the 
incidence of newborn meningitis 
cannot be separated from the pre-
vention of newborn sepsis gener-
ally. In addition, more controlled 
trials are required in the developing 
world with respect to the various 
aspects of management of newborn 
meningitis, particularly fluid man-
agement and the use of adjuvant 
steroids. 
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Meningitis is an extensive inflammatory condition of the 
leptomeninges. Although, it is generally described as 
uncommon, meningitis occurs commonly in the neonatal 
period due to the increased susceptibility of newborn 
babies to severe infections.1 Neonatal meningitis is as-
sociated with significant mortality and severe morbid-
ities.  
 
The overall incidence of meningitis in England and 
Wales has not changed remarkably from the known 0.2 
– 0.4 cases/1000 live births over the last three deca s. 
2,3 These are similar to data obtained from other parts of 
the developed world. Although, consistent incidence 
rates are not available in most parts of the developing 
world, the few available ones are higher compared to the 
developed world. For instance, in Nigeria, the incidence 
of neonatal meningitis in the middle belt was reported to 
be 1.9/1000 live births four and 6.5/ 1000 live births in 
north-eastern Nigeria. 5 Similarly, the incidence rate 
reported in the Panama in the mid-nineties was 3.5 
cases/1000 live births.6     
 
While the incidence has not changed remarkably, there 
has been a significant decrease in the mortality associ-
ated with meningitis over the last two decades due to 
improved antibiotic therapy and supportive care in most 
parts of the developed and industrialized world. On the 
contrary, morbidity has not changed significantly over 
this same period, even, in the developed world. The per-
sistently high morbidity rate among the survivors of 
neonatal meningitis remains a major clinical issue and 
the need to minimize these morbidities is a challenge. 2,3  
 
Although, mortality rates in newborn meningitis vary by 
region, the known rates in the various regions of the
world are not markedly different. For instance, mortality 
rates included 0.7–1.9 ⁄ 1000 live births in sub-Sahar n 
Africa, 0.33–1.5 in the Middle East and North Africa 
and 0.4-2.8 in the Americas and Caribbean.7 Mortality in 
the developed world had dropped from close to 50% to 
about 10% over the last decade whereas morbidity  
remains high at 15 to 60% among the survivors.8  
Although, under-reporting is a challenge in the develop-
ing world, mortality associated with neonatal meningitis 
also varies between 30% and 60% while morbidity fig-
ures vary greatly. Five to seven a high proportion of the 
survivors in neonatal meningitis develop chronic handi-
capping conditions with serious medical and psycho-
social implications such as cerebral palsy, mental retar-
dation, seizure disorder, hemiplegia, deafness and bli -
ness. 5, 9  
 
Although, bacterial meningitis is an important cause of 
newborn death globally, the burden of neonatal sepsi  
and meningitis is most pronounced in the resource-poor 
parts of the world where the disease constitutes a signifi-
cant proportion of neonatal admission and deaths.10,11 
 In spite of the similarity in the pathology and patho-
genesis of meningitis in childhood, there are peculiari-
ties with regard to the diagnosis and management of 
newborn bacterial meningitis. This review aims to high-
light the challenges in the diagnosis and management of 
bacterial meningitis in the newborn in comparison with 
older children. Research issues which may possibly 
proffer solutions to the alarming high prevalence of neu-
rologic sequelae and poor quality of life among the sur-




Symptoms and signs 
 
Bacterial meningitis can be extremely difficult to diag-
nose in the newborn because the symptoms and signs 
are often subtle and non-specific at the early stage of the 
disease. The clinical presentation of meningitis is indis-
tinguishable from that of sepsis without meningitis. The 
early symptoms of meningitis include pyrexia, poor 
feeding, vomiting, lethargy or irritability. These clinical 
features may also characterize other newborn disorders 
such as hypoxic-ischaemic encephalopathy and meta-
bolic derangements such as hypoglycaemia. Therefore, 
distinguishing between early meningitis and other no-
natal illnesses mentioned above may be challenging and 
this is associated with the tendencies to frequently under
-diagnose meningitis in the newborn.  
 
With the progression of the disease, bulging fontanelle, 
shrill cry, apnoeas, seizures, opisthotonus and coma may 
occur. 12 Although, these features are more specific fea-
tures of meningitis and thus, facilitate diagnosis on clini-
cal grounds, they occur quite late in the disease. Instruc-
tively, the classic signs of meningeal irritation i the 
older children, such as neck stiffness and positive Ker-
nig sign or Brudzinski sign are often absent and unreli-
able among infants. Thus, the latter features should not 
form the core of clinical diagnosis of meningitis in the 
newborn. Due to the low sensitivity and specificity of 
the clinical predictors of this severe infectious di ease, 
laboratory diagnosis is indispensable. 12, 13  
 
Bacteriology of newborn meningitis 
Microbiology 
 
In consonance with sepsis, the bacterial aetiology f 
neonatal meningitis differs between the developing a d
the developed world. In most developed countries, the 
leading pathogen in newborn meningitis is Group B 
Streptococcus (GBS). Others include Escherichia coli, 
Listeria monocytogenes, other coliforms and lately, 
Streptococcus pneumoniae.1, 8, 14 Data obtained from 
England and Wales from 1985 to 1987 and from 1996 to 
1997 showed very little change in the pattern of bacterial 
aetiology of neonatal meningitis over this period. GBS 
accounted for 39% to 48% of all cases. Others included 
Escherichia coli (18% to 26%), Streptococcus pneumo-
niae (6%) and Listeria monocytogenes (5% to 7%). 2, 3 
In a more recent French National survey, the leading 
pathogens in newborn meningitis included GBS (59%), 
Escherichia coli (28%), Gram-negative bacilli apart 
from Escherichia coli (4%), other Streptococcus apart 
rom GBS (4%), Neisseria meningitidis (3%) and  
Listeria monocytogenes (1.5%). 15  
 
The pattern of bacteriological aetiology in neonatal men-
ingitis differs in terms of the spectrum of organisms as 
well as the relative prevalence of individual organisms 
causing meningitis in most parts of the developing 
world.  Escherichia coli was earlier reported as the lead-
ing aetiology in Nigeria16 and more recently in Kenya.17 
Although E. coli was also commonly isolated in Nigeria, 
Staphylococcus aureus predominated in two other Nige-
rian reports.4, 5 In addition, some reports of GBS pre-
dominance have also been made in parts of the develop-
ing world like Zimbabwe, Kenya and China. 17 - 19 Inter-
estingly, none of the studies from Nigeria4, 5, 16 reported 
GBS as aetiology of neonatal meningitis. Even most 
recent studies of newborn sepsis in Nigeria did not fi d 
GBS or reported very few cases. 20 - 23  
 
Listeria monocytogenes is also uncommonly encoun-
tered in this part of the world. 17 On the other hand, 
Gram negative bacilli (with the exception of E. coli) 
have a global distribution but appear more common in 
the developing world, probably for reasons of poor hy-
giene.  
 
The emergence of unusual organisms like Haemophilus 
influenza in Nigerian babies with meningitis5, 24 poses 
new challenges in the treatment of newborn meningitis 
in this population. This organism is not usually taken 
into consideration when planning empirical antibiotic 
treatment for newborn meningitis in Nigeria. This may 
constitute technical delay in the commencement of ap-
propriate antibiotic therapy in possible cases of Haemo-
philus influenzae infection among newborns.  
The highlighted differences in the aetiology of meningi-
tis between the developed and developing world may be 
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explained in terms of population differences in therate 
and pattern of colonization, genetic differences in im-
mune response and differences in laboratory techniques 




Positive bacteriologic culture of the cerebrospinal fluid 
(CSF) is the gold standard diagnostic procedure for bac-
terial meningitis. In the absence of bacteriologic culture 
facilities, Gram stain of CSF may also provide usefl 
information upon which initial decisions on diagnosis 
and management can be based. Blood culture may also 
be positive in 40–60% of meningitis cases. 17, 19, 26  
 
The definitive method for diagnosis of meningitis lies in 
the chemistry and bacteriologic culture of the CSF since 
the clinical features of newborn meningitis are largely 
non-specific and blood culture may not always be as 
stated above. There have been controversies about the 
indications for lumbar puncture (LP) in newborn sepsis. 
Current concessions appear to be pivoted on the fact 
that, LP is only useful as part of the work-up for late-
onset sepsis or when infants with early-onset sepsi have 
clinical features suggestive of meningitis. Available 
evidence is not in support of the use of LP in routine 
sepsis work-up for healthy babies with presumed sepsi . 
27 Unlike in the older child, raised intracranial pressure 
rarely occurs in newborn meningitis since the open su-
tures and fontanel allows expansion of the cranium 
when pressure is building up. Thus, the exclusion of 
elevated intracranial pressure prior to LP may not be a 
major concern in the newborn. Nevertheless, compro-
mised cardio-respiratory functions are clear contrai di-
cations to performing LP in critically ill infants. How-
ever, a modified left lateral position with the hip flexed 
to 90⁰ but without flexion of the neck has been proposed 
as useful for LP in the presence of respiratory embar-
rassment. 28 In all situations, when meningitis is sus-
pected, inability to perform LP should not delay appro-
priate antibiotic treatment. 
 
When it is available, the CSF specimen should be exam-
ined macroscopically for turbidity and microscopically 
for the presence of bacterial organisms. Instructively, 
turbidity of the CSF is determined by the number of pus 
cells present in the fluid though the number may vary 
widely. Therefore, when clinical suspicion is strong, 
microscopic examination should take precedence over
macroscopic examination. Although, Gram stain may 
reveal the pathogens in more than three-quarter of cases, 
bacteriological culture is the gold standard for diagnos-
ing meningitis in the absence of prior exposure to antibi-
otics. Abnormalities in cell count and biochemical p -
rameters such as glucose and proteins are also important 
for making diagnosis. Due to physiological variations in 
the biochemical and cellular parameters of newborn 
CSF, caution needs to be exercised in interpreting the 
parameters. The white cell counts in the newborn CSF 
has been shown to be age-specific.29  
Thus, CSF cell count needs to be interpreted with cau-
tion in the diagnosis of neonatal bacterial meningit s. 
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Similar caution has been raised with respect to CSFglu-
cose and protein concentrations among preterm babies 
with meningitis. 30 Indeed, there have been reservations 
about the use of the CSF glucose and protein parameters 
in making the diagnosis of meningitis or assessing the 
success of treatment of meningitis because of the high
variability in the values of the CSF parameters.26 In a 
large study, babies with meningitis had CSF cell count 
of 0 to 15,900/mm3, glucose ranging from 0 to 199mg/dl 
and protein ranging from 41 to 1964mg/dl compared to 
0 to 90,000/mm3, 0 to 1089mg/dl and 3 to 4122mg/dl 
respectively among normal babies. 26 Instructively, stud-
ies are yet to show to what extent this variability truly 
affects the diagnosis of meningitis in the newborn. In 
spite of the challenges posed by the variability high-
lighted above, most practitioners still stick to the tradi-
tional cut-off values of the various parameters: white 
cell count > 32/mm3 with more than 60% polymor-
phonuclear cells, proteins > 170mg/dl in preterm babies 
(or > 150mg/dl among term babies) and glucose < 50%
of serum glucose, determined just prior to lumbar tap.   
 
The Interpretation of neonatal CSF parameters is also
difficult when the fluid is blood stained, as this obvi-
ously changes both the cellular and biochemical con-
stituents of the fluid. One of the traditional methods of 
resolving the debacle is to count both the erythrocytes 
and leucocytes in the fluid and use the physiological 
ratio of 700 erythrocytes to one leucocyte as the cut-off 
point from normal. In a more recent US study, it was 
reported amongst others that, in a cohort of newborn 
infants, CSF protein increased by 2mg/dl for every 1000 
erythrocytes in the CSF even in spite of the presence of 
pleocytosis. 31 This method may not require sophisti-
cated kits or personnel and thus, can be studied further 
for its clinical applicability in the developing world.   
The CSF gets sterilized rapidly following exposure to 
antibiotics. It takes just about two hours for meningo-
coccus, and up to six hours for pneumococcus. 32 This is 
important in the situations of pre-hospital care antibiotic 
use which is common in parts of the world where antibi-
otic use is poorly regulated. The CSF culture findings 
may be altered by prior antibiotic use but antibiotics 
rarely interfere with CSF protein or glucose. In this 
situation, bacterial antigen detection serological methods 
would be most useful. Even in the absence of prior ex-
posure to antibiotics, delay in processing CSF for up to 
four hours, has been reported to cause progressive de-
cline in CSF glucose and white cell counts. 33 This is 
very relevant to the practice in the developing world 
where inadequate laboratory services (in terms of per-
sonnel, infrastructures and equipment) may warrant de-
lays in processing CSF samples. Therefore, practitioners 
in this part of the world need to take these variables into 
consideration when interpreting CSF parameters.   
 
To a large extent, the use of molecular and serologic 
methods such as the polymerase chain reaction (PCR), 
which does not require the presence of live organisms 
for diagnosis, have improved the diagnosis of meningitis 
on the CSF. Commercial kits for performing the sero-
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logic tests for Streptococcus pneumoniae, Group B 
Streptococcus, E. coli and Haemophilus influenzae are 
available in most laboratories in the developed world but 
not yet in the resource-poor parts of the developing 
world. PCR has been shown to detect 100% cases of 
bacterial meningitis in a cohort of Greek children while 
culture detected only 21.4%. 34 In addition, PCR, may, 
in the future be used to prognosticate since a study of 
quantitative PCR on blood, showed a correlation be-
tween disease severity and meningococcal bacterial 
DNA load among older children. 35 Although, meningo-
coccus is not a common cause of newborn meningitis. 
However, it is very likely that a similar principle may 
apply to other pathogens with respect to PCR and sever-




Neuro-imaging is required for the diagnosis of intra-
cerebral collections, structural focal lesions and ven-
tricular dilatation. These features may affect response to 
antibiotic treatment of meningitis. Therefore, poor clini-
cal response despite adequate therapy is an indication 
for neuro-imaging in newborn meningitis. The most 
basic of such imaging method in use in the developing 
world include trans-fontanelle ultrasonography and com-
puterized tomographic (CT) scans of the brain. Unfortu-
nately, the wide variation in the size of normal later l 
ventricles make CT scans less reliable in diagnosing 
truly dilated ventricles in the newborn. 36 More efficient 
imaging facilities like the Magnetic Resonance Imaging 
are unfortunately, not available for routine use in most 




Full blood count, C-reactive protein (CRP), clotting 
studies, and urea and electrolytes are useful ancill ry 
tests in sepsis work-up. Leucopaenia and elevated CRP
are known to be more consistent with the diagnosis f 
severe bacterial infection in the newborn. 37 Elevated 
procalcitonin (with sensitivity of 90% and specificity of 
65%) was recently shown, in a systematic review, to 
have good diagnostic accuracy especially for late-onset 




The three major aspects of treatment of bacterial menin-
gitis include (1) antibiotic therapy (2) fluid restric ion 
(3) adjunctive therapy. Central to the understanding of 
the relevance of these major aspects is the basic pthol-
ogy and pathogenesis of bacterial meningitis. Following 
the penetration of pathogens into the subarachnoid 
space, the destruction of the bacterial cell walls in the 
meninges may occur spontaneously or following antibi-
otic treatment. The destruction of the bacterial cell walls 
results in the release of antigenic components such as 
peptidoglycan and teichoic acid into the subarachnoid 
space. The released bacterial toxins and cell wall com-
ponents provoke the release of cytokines such as inter-
leukins (IL-1β), tumour necrosis factor-γ (TNF) and 
platelets aggregation factor (PAF). These agents in urn, 
offset an inflammatory cascade characterized by in-
creased vascular permeability, polymorphonuclear mi-
gration and activities and production of exudates and
cellular debris. Ultimately, these inflammatory events 
result in cerebral oedema, elevated intracranial pressure, 
reduced cerebral perfusion, cerebritis, neuritis and vas-
culitis.39 The end-result of all these pathologic features 
include ischaemia, infarction and atrophy of neural tis-
sues. Short and long-term morbidities occur in infants 
with bacterial meningitis as a result of the aforemen-
tioned pathologic changes. Some of the acute morbid-
ities in meningitis include cerebral oedema, subdural 
effusion, subdural empyema, venous sinus thrombosis, 
cranial nerve palsies and hydrocephalus. Long term neu-
rologic deficits in meningitis include hearing loss, corti-
cal blindness, strabismus, speech disorders, behaviour l 
disorders, motor deficits particularly hemiplegia, mental 




The goal of antibiotic treatment in meningitis is rapid 
sterilization of the CSF. This explains why antibiotic 
therapy is highly recommended when meningitis is 
clinically suspected even when definite investigations 
are not feasible or delayed. In standard practice wh re 
microbiological diagnosis could be reliably made, the 
choice of antibiotic depends on the organism isolated. 
However, in most cases especially in most parts of the 
developing world, the initial treatment is usually empiri-
cal pending the availability of sensitivity reports from 
the laboratory. This empirical treatment depends on the 
known epidemiology of the likely organisms as well as 
the local antibiotic resistance patterns. When the blood-
brain barrier is inflamed as it occurs in meningitis, the 
permeability is increased and the penetration of most 
antibiotics into the CSF is improved. It is important that, 
the antibiotic chosen for empirical treatment should have 
good penetration into the CSF and achieve adequate 
minimum bactericidal concentration (MBC) for the or-
ganism.40 These properties are important for rapid ster-
ilization of the CSF which impacts on the survival of the 
affected infants.  
 
The traditional treatment of neonatal meningitis involves 
ampicillin and gentamicin. Although, the penicillins 
generally have poor CSF penetration when the menings 
are inflamed,41 adequate concentrations can be delivered 
into the CSF with more frequent and higher doses.  
On the other hand, gentamicin readily penetrates th 
inflamed blood-brain-barrier but rarely achieves the 
minimum bactericidal concentration for the pathogens.  
Increasing the therapeutic dose of gentamicin in order to 
achieve higher minimum bactericidal concentration in 
the CSF may be harmful since the drug ordinarily has a 
narrow therapeutic index and can readily cause ototoxic-
ity and nephrotoxicity.41 This is particularly challenging 
in the resource-constrained parts of the world where 
facilities for monitoring serum drug levels are not avail-
able. In an attempt to circumvent this challenge, trials of 
intraventricular administration of antibiotics in meningi-
shown to have high resistance to ampicillin and gen-
tamicin. 17, 19 These reports have significant implications 
for the principle of using ampicillin and gentamicin for 
the empirical treatment of newborn meningitis in this 
part of the world.  
 
Duration of treatment and choice of antibiotic 
 
Antibiotic therapy often requires modification once anti-
biotic susceptibility testing becomes available. The anti-
biotic treatment of meningitis in the newborn is tradi-
tionally prolonged because of the challenges of penetra-
tion of CSF and achievement of minimum bactericidal 
concentration earlier mentioned. At present, there is no 
statistical evidence to specifically guide the duration of 
antibiotic treatment in neonatal meningitis. However, 
the general principle is that the duration of antibio c 
treatment depends on the organism isolated. For Gram 
negative bacilli, parenteral administration of antibiotics 
should be continued for a minimum of three weeks or 
for 14 days after the sterilization of the CSF. 37 This 
prolongation of therapy is important because of delay d 
sterilization of the CSF in Gram-negative bacilli menin-
gitis. The latter fact may explain the high mortality and 
poorer outcome associated with Gram negative bacilli 
meningitis. For GBS, the minimum duration of treat-
ment is 14 days while Staphylococcus aureus meningitis 
should be treated for up to three weeks in order to re-
duce the risk of cerebral abscess formation.  
 
It is recommended that LP should be repeated 24 to 48 
hours after the commencement of therapy to ascertain 
sterilization of the CSF. However, with cefotaxime and 
ceftriaxone, an Australian study of childhood meningitis 
demonstrated that the lowest CSF concentrations of both 
drugs were several times higher than the minimum bac-
tericidal concentrations for the organisms 
(meningococcus, pneumococcus and Haemophilus influ-
enzae). 47 On the basis of these findings, the authors rec-
ommended that repeat LP was not necessary when treat-
ing meningitis due to these organisms with either of 
these drugs. Thus, it may be attractive to recommend 
either of these drugs for the empirical treatment of new-
born meningitis in places where significant resistance to 
the drugs have not been reported and avoid repeat LP. 
 
In some unusual cases, inflammatory changes in the 
CSF may persist despite adequate antibiotic treatment as 
a result of obstructive ventriculitis, subdural empyema, 
cerebral abscess or intracranial vessel thrombi. Persis-
tent CSF inflammation is an indication for neuroimaging 
and review of antibiotic therapy. From the results of 
neuroimaging, other therapeutic measures like surgical 
interventions may be required in the care of the meningi-
tic infant. In addition to neuroimaging, antibiotic ther-
apy may need to be prolonged. Subsequent CSF exami-
nation is unnecessary if the CSF has been sterilized by 
48 hours of therapy and the clinical course has been  
satisfactory.   
 
Repeat LP at the end of therapy, hitherto recommended, 
is currently unpopular in the UK. 48 A study of a small 
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tis were conducted but the findings were disappointing 
with observed increased mortality. 42, 43  
 
The WHO recommended initial antibiotic combination 
of a penicillin (e.g. ampicillin or penicillin G) and an 
aminoglycoside (e.g. gentamicin) or a third-generation 
cephalosporin (e.g. ceftriaxone or cefotaxime) for the
treatment of meningitis in young infants aged < 
60days.44 A recent systematic review45 which compared 
the use of third generations and the traditional antibiot-
ics (ampicillin, penicillin and chloramphenicol in vari-
ous combinations), found no significant difference in 
terms of death, deafness and treatment failures among 
subjects with meningitis. However, the review covered 
all studies of bacterial meningitis irrespective of age 
hence the difficulty in generalizing the results of the 
review. 
 
In the developed world, the first line therapy is usually 
ampicillin with gentamicin or ampicillin with cefo-
taxime or ceftriaxone although the latter has the ten-
dency to cause displace bilirubin from albumin binding 
sites. 37 The third generation cephalosporins are effective 
on a wide range of pathogens causing meningitis, in-
cluding the aminoglycoside-resistant strains. Unfortu-
nately, this class of antibiotics has not been shown to be 
particularly effective on Listeria monocytogenes, thus, 
they are not recommended for monotherapy in place  
where Listeriosis is common. Nevertheless, they have 
good blood-brain-barrier penetration and achieve ad-
quate minimum bactericidal concentrations for most 
organisms in the CSF. 46 Ampicillin is effective on GBS, 
the coliforms and Listeria monocytogenes. Although, 
Listeria monocytogenes and GBS are reportedly uncom-
mon in most parts of the developing world, most physi-
cians also adopt the combination of ampicillin and cefo-
taxime in the empirical treatment of meningitis in the 
newborn. The third-generation cephalosporins 
(cefotaxime and ceftriaxone) are active against the major 
pathogens of neonates worldwide, including aminogly-
coside-resistant strains. A recent Nigerian study repo ted 
remarkable sensitivity of pathogens in newborn septi-
caemia to ceftriaxone, cefotaxime and ceftazidime.23 
Thus, these drugs can also be reliably used in the em-




Antibiotic resistance is a major challenge confronting 
practitioners worldwide.25 This, to a large extent, makes 
global recommendations on the choice of drugs which 
are useful for the empirical treatment of severe inf c-
tions in the newborn difficult. A recent study of new-
born septicaemia in Sagamu, Nigeria reported overall 
resistance of 70.3% to ampicillin and 43.6% to gen-
tamicin. 23 Specifically, the resistance of Staphylo-
cocccus aureus to ampicillin and gentamicin were 66.7% 
and 37.5% respectively in the report from Sagamu.  
This observation is important in view of the predomi-
nance of Staphylococcus aureus a  a leading pathogen in 
newborn meningitis as reported in another Nigerian 
study. 5 In addition, the Gram negative bacilli have been 
number of babies also showed that a repeat LP was un-
necessary if clinical response to treatment was sati fac-
tory. This suggestion was based on the fact that neither 
normal CSF at the end of treatment nor abnormal CSF
findings accurately predicted cure or relapse.49 There-
fore, practitioners need to weight the benefit of a repeat 
LP at the end of treatment against the attendant risks.   
 
Trials of shorter duration of treatment are on-goin 
among older children. A randomized trial among 100 
infants with meningitis showed that four days of cetri-
axone treatment is as effective as seven days with no 
difference in complications and treatment failures.50 A 
more recent double-blind randomized trial in Malawi, 
showed no significant difference in relapse or treatment 
failure rate among children with meningitis treated with 
antibiotics for five days or 10 days. 51 This study sug-
gested that discontinuation of antibiotics after the fifth 
day of ceftriaxone among children of post-neonatal ge
who remained stable was safe. Similar trials in the new-
born period are highly desired.  
 
Similarly, a randomized controlled trial of seven-day 
versus 14-day antibiotic treatment for neonatal sepsi  
showed similar treatment failure rates in both groups 
prompting a recommendation of shorter duration of 
treatment.52 For clinical usefulness, large scale con-
trolled trials are also required. It will be interesting to 
know if these findings may be safely extrapolated to 
other invasive newborn diseases like meningitis.  
 
Use of dexamethasone 
 
Bacterial meningitis is characterized by high mortality 
and severe neurologic sequelae among most survivors. It 
is believed that most of the sequelae are as a result of the 
damage to neural tissue during the acute inflammatory 
process that characterizes bacterial meningitis. There-
fore, the use of corticosteroids as adjuncts in the treat-
ment of bacterial meningitis is intended to attenuate the 
acute inflammatory process, minimize tissue damage 
and ultimately improve clinical outcomes both in the 
short and long term.  
 
The timing of administration of corticosteroids in men-
ingitis is also important in the determination of its effi-
cacy. In childhood bacterial meningitis, the administra-
tion of intravenous dexamethasone before or along with 
the first dose of antibiotics has been reported to be more 
beneficial compared to administration after the com-
mencement of antibiotics.53 It is standard practice to 
administer dexamethasone in divided doses for four 
days. There is no evidence that the drug is more effec-
tive when given for longer or shorter periods but the risk 
of adverse effects appears to increase with the duration 
of administration.54  
 
Although, the use of adjuvant corticosteroids has been 
traditionally employed in the treatment of meningitis 
among children of post-neonatal age and adults, ran-
domized and non-randomized studies have given con-
flicting reports concerning the effectiveness of adjuvant 
dexamethasone in improving the survival and reducing 
neurologic deficits including hearing loss in meningitis 
among children, particularly in low-income countries.55 
At present, the best evidence for the benefits of dexa-
methasone is in H influenzae type b meningitis where 
better audiologic outcome has been clearly demon-
strated.56 
 
Studies of the use of dexamethasone in meningitic new-
borns are particularly sparse. Therefore, current treat-
ment guidelines for newborn meningitis exclude adjunc-
tive dexamethasone therapy. Nevertheless, there are 
reports of likely usefulness of dexamethasone in the 
reduction of overall mortality as well as reduction in 
neurologic sequelae among survivors of newborn men-
ingitis. A non-randomized study of Australian infants 
between 1953 and 1961 reported mortality rate of 41% 
in the steroid-treated group compared with 75% of non-
treated group. Despite better survival, there was no im-
pressive difference in the occurrence of neurologic se-
quelae in both groups.57 Another non-randomized study 
of newborns with bacterial meningitis in Nigeria be-
tween 1992 and 1995 revealed lower mortality and 
higher frequency of full recovery among babies treated 
with adjuvant dexamethasone. 5 These two studies, de-
spite their demonstration of usefulness of dexa-
methasone therapy in the newborn, could not be useda  
a universal guide for treatment because they were not 
randomized controlled trials. Unfortunately, the most 
frequently cited study which questioned the usefulness 
of dexamethasone was randomized and controlled.58 The 
latter study of babies with meningitis in Jordan showed 
similar case fatality rates (22% Vs 28%) and neurologic 
sequelae (30% Vs 39%) among babies treated with or 
without dexamethasone.  
 
Several other studies among older infants and children 
have demonstrated conflicting reports about the efficacy 
of adjunct dexamethasone therapy in meningitis. 53, 59The 
findings from these studies could not be scientifically 
extrapolated to newborns because subgroup analysis wa  
not carried out for children aged 6 weeks to 12 weeks. 
The extrapolation could have been useful given the un-
derstanding that the immune characteristics and range of 
pathogens causing serious infections at that age (6 
weeks to 12 weeks) are usually similar to those of the 
newborn period. Nevertheless, till date, there is no clear 
high-power statistical evidence that the use of corti s-
teroids in neonatal meningitis truly improves the out-
come and prevents neurologic complications of the dis-
ease. Neither is there any clear high-power statistical 
evidence that the use of corticosteroids in neonatal men-
ingitis truly lacks benefits in terms of the outcome of the 
disease. Systematic reviews of the available controlled 
trials are desired. 
 
Use of intravenous fluids 
 
Other important supportive care in the management of 
meningitis includes anticonvulsant therapy, use of in -
tropes and fluid management. Unfortunately, there are 
no controlled clinical trials with respect to the use of 
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these measures among newborns. In general, it is a com-
mon practice to restrict fluids to two thirds or thee quar-
ters of the daily maintenance during the management of 
childhood meningitis. The basis for this practice is the 
need to reduce the likelihood of the syndrome of inap-
propriate secretion of antidiuretic hormone (SIADH). 
SIADH is characterized by hyponatraemia, fluid reten-
tion and a tendency to worsen cerebral oedema in men-
ingitis. Therefore, practitioners reduce fluid therapy in 
children with meningitis in the hope of preventing 
SIADH.  
 
The true benefits of this practice are yet to be docu-
mented. In the first place, the pathogenesis of SIADH in 
meningitis remains unclear and the reported incidence of 
SIADH in meningitis varies considerably. These facts 
cast a lot of doubt on the usefulness of the practice of 
fluid restriction in this instance.  
 
In addition, a significant proportion of children with 
meningitis particularly after delay in presentation pre-
sents with dehydration or hypovolaemia and are in dire
need of fluid resuscitation. 60 It will be dangerous to rig-
idly restrict fluid therapy in such situation.  
Nevertheless, the clinical dilemma of whether fluids 
should be restricted or not continues to generate dispari-
ties in the pattern of clinical practice as well as difficul-
ties in interpreting mortality figures in childhood menin-
gitis.  
 
Current thinking suggests that the increased extracellular 
fluid, the appropriate increased secretion of ADH, and 
mild systemic hypertension occurring in situations of 
raised intracranial pressure are compensatory mecha-
nisms. These physiologic changes are required to over-
come the raised intracranial pressure and to maintain 
adequate cerebral blood flow and perfusion. Therefore, 
fluid restriction is likely to reduce the efficacy of the 
compensatory mechanisms and thus, increase the likeli-
hood of adverse outcome. 61 A systematic reviews of 
controlled trials among children showed no significant 
difference in number of deaths and acute severe neuro-
logical sequelae among maintenance-fluid and restricted
-fluid groups. 62 Further subgroup analyses in the same 
review showed statistically significant difference in fa-
vour of the maintenance-fluid group in terms of spastic-
ity, seizures at 72 hours and 14 days and chronic severe 
neurological sequelae at three-months follow up.   
The current body of scientific evidence no longer sup-
ports the practice of fluid restriction in the management 
of childhood meningitis, as there are no benefits either 
immediately or on long term basis. Rather, it is more 
attractive to carefully assess infants with meningit s for 
possible dehydration, correct dehydration appropriately, 
ensure adequate fluid intake but prevent overhydration.  
 
Treatment of raised intracranial pressure 
 
Raised intracranial pressure (ICP) is a well recognized 
complication of meningitis among older children but 
this is not a cause for concern among newborns with
meningitis. Measures aimed at reducing intracranial 
pressure are only used among older children who are 
more at risk of significantly raised intracranial pressure 
as a result of non-expansible cranium. Osmotic agents 
shift fluids from the extravascular to the intravascular 
space, resulting in a reduction of intracranial pressure. A 
recent study among children aged 2 months to 12 years 
suggested that glycerol-induced increment in osmolality 
and reduction in CSF volume may be mechanism by 
which glycerol reduces intra-cranial pressure.63 Initial 
placebo-controlled trials of glycerol with or without 
dexamethasone in childhood meningitis have demon-
strated overall better neurologic sequelae among the 
cases but not with respect to deafness. 64 More trials of 
other osmotic diuretics such as 20% mannitol, glycerol 
and hypertonic saline in the treatment of raised ICP are 
still on-going in different parts of the world. It may 
seem, by virtue of current knowledge, that meningitc 
neonates do not desperately require osmotic therapy. 
However, controlled trials are still needed to prove this 




Neonatal meningitis is characterized by high mortality 
and severe morbidities which cause handicaps. A study 
of 111 children aged between 9 and 10 years who sur-
vived neonatal meningitis in England and Wales be-
tween 1985 and 1989 showed worse general outcome 
compared to non-meningitic matched controls. The sur-
vivors of neonatal meningitis had less mean intellig nce 
quotient, higher frequency of motor impairment, sei-
zures, hydrocephalus and hearing loss.9 The spectrum of 
neurologic sequelae reported in the UK study was not 
different from the pattern reported from Nigeria.5  
 
Given the background of generally poor outcome in neo-
natal meningitis, prevention is highly desired. The pr -
ventive measures in newborn meningitis cannot be sepa-
rated from those of newborn sepsis generally. These 
may include routine screening of pregnant women for 
urinary tract infection, early intervention following 
spontaneous rupture of fetal membranes and hygienic 
birth generally. For the developed world and other 
places where GBS is reportedly predominant, prenatal 
screening for GBS, appropriate treatment and intrapar-
tum antibiotic prophylaxis are useful practices.65 Instruc-
tively, these practices only reduce the burden of early-
onset neonatal disease whereas GBS meningitis com-
monly presents as late-onset sepsis. 
 
Early recognition and prompt commencement of appro-
priate antibiotic therapy are also desired to minimze the 
risk of poor outcome in neonatal meningitis. This consti-
tutes major challenge in most parts of the developing 
world where most ill babies present late to the hospitals. 
The advent of vaccines against Haemophilus influenzae 
and Streptococcus pneumoniae infections might have 
changed the epidemiology of childhood meningitis in 
the developed world but these have not impacted on the 
newborn period where the vaccines are not routinely 
indicated.     
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